CBio now Invion after completing merger
07 September, 2012 by Dylan Bushell-EmblingAustralian drug developer CBio has completed its merger with US-based Inverseon and formally changed its name to Invion (ASX:IVX).
AstraZeneca evaluating Starpharma cancer drugs
07 September, 2012 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) cancer drug development platform has attracted the attention of UK pharmaceutical giant AstraZeneca.
FDA decision on MoxDuo expected mid-2013
06 September, 2012 by Dylan Bushell-EmblingAfter being cleared to submit existing trial data to back up its IND application for pain formulation MoxDuo IR, QRxPharma (ASX:QRX) now expects the US FDA to make its decision in mid-2013.
Iluvien may get UK NHS listing
06 September, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera has scored a win in efforts to gain UK acceptance for the Iluvien micro-insert as a treatment for chronic diabetic macular edema (DME).
AusBiotech announces 2012 AGM and Board elections
06 September, 2012 by AusBiotechAusBiotech has announced it will hold its annual general meeting at the AusBiotech 2012 national conference in Melbourne on Thursday 1 November 2012 at 1:00pm, where business will include the outcome of the election for two directors to join the AusBiotech Board.
NSW kicks off medical devices fund
06 September, 2012 by Dylan Bushell-EmblingThe NSW government has launched a seven-figure fund to encourage the development and commercialisation of innovative medical devices in the state.
Avita launches capital raising for spray-on skin
05 September, 2012 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) will raise up to $10m through a placement and SPP to support marketing and US commercialisation efforts for its ReCell Spray-On Skin technology.
AusBiotech 2012: Program now available for industry event of the year
04 September, 2012 by AusBiotechThe event, to be held in Melbourne – 30 October - 2 November 2012 – will feature expert speakers from overseas and Australia, who will speak on investment, public policy, industry experiences and business development.
Innate Immunotherapeutics to raise US$10m for Australian MS trial
03 September, 2012 by Dylan Bushell-EmblingNew Zealand's Innate Immunotherapeutics has launched a US$10 million ($9.75 million) capital raising to help fund an Australian trial of a prospective treatment for progressed multiple sclerosis.
Azure Healthcare swings to profit for FY12
03 September, 2012 by Dylan Bushell-EmblingAzure Healthcare (ASX:AZV), shed of its unprofitable audio visual business, swung to a $744,000 net profit for FY12.
GTG launches new patent infringement suit
31 August, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has filed a patent suit against California's Reproductive Genetics Institute, in the newest enforcement effort for its non-coding DNA patents.
UQ researchers get funding for plant antiviral
31 August, 2012 by Dylan Bushell-EmblingCommercialisation Australia has granted a $50,000 grant to help bring Nexgen – an anti-viral technology for plants developed at The University of Queensland – to market.
Productivity Commission reviews compulsory licensing in the patents system
30 August, 2012 by AusBiotechThe Productivity Commission’s review into compulsory licensing in the patents system is now examining whether and how to ensure access to patented technology, while maintaining the patent incentive to create and protect new technology.
Bluechiip secures supply deal with US CRO
29 August, 2012 by Dylan Bushell-EmblingTracking chip technology developer Bluechiip (ASX:BCT) has forged a strategic partnership with US CRO Gentris Corporation. Bluechiip has agreed to provide Gentris with its eponymous temperature sensing and tracking chips, which are initially being developed for cryogenic sample management.
Expert endorses Alchemia oncology spin-off
29 August, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has filed papers with ASIC regarding the proposed spin-off of its oncology business, after the independent analysts hired to assess the deal concluded that the demerger is in shareholders' best interests.
